Related Experiment Video
Updated: May 14, 2026

Ex Vivo Corneal Organ Culture Model for Wound Healing Studies
Published on: February 15, 2019
Targeting the epithelial cells in fibrosis: a new concept for an old disease
Solange Moll1, Lyubov Chaykovska, Matthias Meier
1Institute of Clinical Pathology, University Hospital Geneva, Geneva, Switzerland.
Abstract:
Fibrosis, which affects millions of individuals worldwide, is a leading cause of organ failure. For 40 years myofibroblasts have been recognized to be the key cellular players in fibrosis. Currently, several pharmaceutical targets are under investigation that may contribute to the activation of myofibroblasts. Recent preclinical and clinical evidence suggests that other components in the fibrotic microenvironment can trigger myofibroblast activation, providing new targets for pharmaceutical intervention. Epithelial cells may represent the most promising cellular phenotype that could be exploited in the design of new anti-fibrotic medicines through their paracrine action on myofibroblasts. The present review briefly highlights this hypothesis and discusses some interesting related pharmacological targets.
Insights
Fibrosis causes organ failure, with myofibroblasts as key cells. Targeting epithelial cells offers a promising new strategy for anti-fibrotic medicines by influencing myofibroblast activation.
Area of Science:
- Fibrosis research
- Cellular biology
- Pharmacological targets
Background:
- Fibrosis affects millions globally, leading to organ failure.
- Myofibroblasts are the primary cellular drivers of fibrosis.
- Existing pharmaceutical targets focus on myofibroblast activation.
Purpose of the Study:
- To review the hypothesis that epithelial cells can be targeted for anti-fibrotic therapies.
- To discuss pharmacological targets related to epithelial cell-mediated myofibroblast modulation.
Main Methods:
- Review of preclinical and clinical evidence.
- Analysis of the fibrotic microenvironment's role.
- Exploration of epithelial cell paracrine signaling.
Main Results:
- The fibrotic microenvironment contains components that activate myofibroblasts.
- Epithelial cells show potential as a therapeutic target via paracrine action.
- New pharmaceutical intervention strategies are emerging.
Conclusions:
- Epithelial cells represent a promising cellular target for anti-fibrotic drug design.
- Modulating epithelial cell paracrine signaling could inhibit myofibroblast activation.
- Further research into these targets may yield novel anti-fibrotic medicines.
Related Concept Videos
Introduction to Fibroblasts
Cirrhosis II: Pathophysiology
Chronic Inflammation: Introduction
Healing I: Introduction
